DAPAS, BARBARA
 Distribuzione geografica
Continente #
NA - Nord America 11.674
EU - Europa 6.653
AS - Asia 5.499
SA - Sud America 542
AF - Africa 161
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 24.593
Nazione #
US - Stati Uniti d'America 11.443
SG - Singapore 1.835
CN - Cina 1.462
IT - Italia 1.362
PL - Polonia 1.128
SE - Svezia 822
DE - Germania 703
UA - Ucraina 510
VN - Vietnam 506
HK - Hong Kong 485
FR - Francia 428
BR - Brasile 406
GB - Regno Unito 362
KR - Corea 337
RU - Federazione Russa 333
FI - Finlandia 280
TR - Turchia 218
BD - Bangladesh 208
NL - Olanda 171
CA - Canada 135
IE - Irlanda 134
IN - India 132
BG - Bulgaria 124
MX - Messico 60
MA - Marocco 57
BE - Belgio 56
JP - Giappone 48
AU - Australia 46
AR - Argentina 41
CH - Svizzera 41
ES - Italia 35
AT - Austria 30
IQ - Iraq 29
ZA - Sudafrica 29
SA - Arabia Saudita 25
PK - Pakistan 22
CZ - Repubblica Ceca 19
SN - Senegal 19
TW - Taiwan 19
IR - Iran 18
EC - Ecuador 17
ID - Indonesia 16
RO - Romania 16
TH - Thailandia 16
VE - Venezuela 16
CL - Cile 15
EG - Egitto 15
PH - Filippine 15
CO - Colombia 13
UZ - Uzbekistan 12
JO - Giordania 11
LU - Lussemburgo 11
DZ - Algeria 10
EU - Europa 10
GR - Grecia 10
IL - Israele 10
KE - Kenya 10
LT - Lituania 10
MY - Malesia 10
RS - Serbia 10
AZ - Azerbaigian 9
PE - Perù 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
KZ - Kazakistan 8
PY - Paraguay 8
DK - Danimarca 7
HR - Croazia 7
HU - Ungheria 7
TT - Trinidad e Tobago 7
NO - Norvegia 6
NP - Nepal 6
PT - Portogallo 6
SI - Slovenia 6
BO - Bolivia 5
EE - Estonia 5
MO - Macao, regione amministrativa speciale della Cina 5
BH - Bahrain 4
GD - Grenada 4
HN - Honduras 4
JM - Giamaica 4
MU - Mauritius 4
PA - Panama 4
AO - Angola 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GE - Georgia 3
KG - Kirghizistan 3
LV - Lettonia 3
MN - Mongolia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AL - Albania 2
CR - Costa Rica 2
ET - Etiopia 2
GT - Guatemala 2
GY - Guiana 2
KH - Cambogia 2
Totale 24.558
Città #
Ashburn 1.191
Ann Arbor 1.064
Singapore 1.064
Warsaw 1.012
Woodbridge 969
Fairfield 834
Chandler 823
Houston 711
San Jose 582
Jacksonville 471
Hong Kong 459
Trieste 439
Wilmington 397
Hefei 384
Beijing 337
Seattle 322
Seoul 321
Cambridge 294
Princeton 227
Boardman 221
Los Angeles 190
Izmir 177
Chicago 155
Santa Clara 146
Ho Chi Minh City 145
Dearborn 139
Columbus 130
Dublin 130
The Dalles 126
Council Bluffs 122
Sofia 122
Hanoi 121
Lauterbourg 121
Moscow 116
Dallas 109
Zgierz 98
Helsinki 95
Milan 86
Munich 83
London 82
Buffalo 80
New York 79
Düsseldorf 75
Frankfurt am Main 69
São Paulo 49
Brussels 48
Casablanca 47
San Diego 47
Atlanta 41
Montreal 41
Orem 40
Redmond 40
North Bergen 39
Turku 33
Phoenix 32
Tokyo 31
Duino-Aurisina 30
Washington 30
Bern 29
Kunming 29
Padova 29
Redwood City 29
Guangzhou 28
Shanghai 28
Ottawa 27
Rome 26
Sydney 26
Bremen 25
Chennai 24
Toronto 24
Da Nang 23
Jinan 23
Denver 22
San Francisco 22
Poplar 21
Grafing 20
Venezia 20
Dakar 19
Haiphong 19
Nanjing 19
Des Moines 18
Naples 18
Verona 17
Dong Ket 16
Johannesburg 16
Manchester 16
Mestre 16
Norwalk 16
Brooklyn 15
Memphis 15
Amsterdam 14
Campinas 14
Falls Church 14
Hebei 14
Nuremberg 14
Paris 14
Portsmouth 14
Roubaix 14
Boston 13
City of London 13
Totale 16.299
Nome #
Polysaccharides for the delivery of antitumor drugs 494
Polymer-mediated delivery of siRNAs to hepatocellular carcinoma: Variables affecting specificity and effectiveness 476
Potential applications of nanocellulose-containing materials in the biomedical field 466
Effect of cystic fibrosis sputum rheology on lungs drug delivery by inhalation 425
GT75 aptamer against eukaryotic elongation factor 1A as potential anticancer drug for castrate-resistant prostate cancer (CRPC). 396
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma 358
Strategies for delivery of siRNAs to ovarian cancer cells 335
Therapeutic potential of Nucleic acid-based drugs in coronary hyper-proliferative vascular diseases 321
Therapeutic potential and delivery strategies for nucleic acid-based drugs 301
The role of the transcription factor E2F1 in hepatocellular carcinoma 295
Strategies to optimize siRNA delivery to hepatocellular carcinoma cells 286
Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs 285
Recent advances in smart biotechnology: Hydrogels and nanocarriers for tailored bioactive molecules depot 284
Serum Response Factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6 281
Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs 273
Mathematical modeling of drug release from natural polysaccharides based matrices 271
Aptameric GT oligomers need to be complexed to ethoxylated polyethylenimine as pre-paired duplexes to efficiently exert their cytotoxic activity in human lymphoblastic cancer cells 270
Current strategies to improve the efficacy and the delivery of nucleic acid based drugs 267
A novel approach based on low-field NMR for the detection of the pathological components of sputum in cystic fibrosis patients 266
Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects 262
Membranes in Drug Delivery 261
Can low field nuclear magnetic resonance be used to monitor lung functionality of cystic fibrosis patients? 255
Characterization of nucleic acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices 255
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. 254
Alcohol reduces MMP-2 in humans and isolated smooth muscle cells. 253
"Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single stranded DNA-binding proteins" 249
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia 248
Drug delivery from polymeric matrices 246
A rapid and specific method to simultaneously quantify eukaryoticelongation factor 1A1 and A2 protein levels in cancer cells 246
Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells 240
Effects of E2F1-cyclinE1-E2 circuit down-regulation in hepatocellular carcinoma cells 238
Translation Elongation 236
Dissecting the expression of EEF1A1/A2 genes in human prostate cancer cells: the potential od EEF1A2 as a hallmark for prostate transformation and progression 235
Combined use of rheology and portable low-field NMR in cystic fibrosis patients 235
Aptamers as nano-targeting delivery devices or anti-cancer drugs for fighting tumours 233
Can rheology be useful in the cystic fibrosis frame 232
PDPG Polymer as a targeted delivery system for siRNAs to hepatocellular carcinoma cells 227
Use of Rheology and portable Low-Field NMR for the monitoring of lung functions in cystic fibrosis patients 226
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials 221
5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway 219
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells 216
Characterisation of nucleid acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices 214
A siRNA targeted against SRF reduce hepatocellular carcinoma cell proliferation, showing its potential use in the growth inhibition of this type of tumor 212
Effects of hypoxia and bed rest on markers of cardiometabolic risk: Compensatory changes in circulating trail and glutathione redox capacity 212
"Charactherization of nucleic acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices" 211
A siRNA targeted against SRF reduce hepatocellular carcinoma cell proliferation, showing its potential use in the growth inhibition of this type of tumor 207
The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade 205
Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing 202
Use of low field nuclear magnetic resonance to monitor lung inflammation and the amount of pathological components in the sputum of cystic fibrosis patients 200
Evaluation of the contribution of the elongational factor 1 A isoforms in hepatocellular carcinoma celss growth 196
Comparison between recombinant baculo and adenoviral-vectors as transfer system in cardiovascular cells 195
Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells 195
Bortezomib effect of E2F and cyclin family members in human hepatocellular carcinoma cell lines 193
Epigenetic and miRNAs dysregulation in prostate cancer: the role of nutraceuticals. 191
Synthesis and Spontaneous Polymerization of Oligo(ethyleneglycol)-Conjugated Benzofulvene Macromonomers.A Polymer Brush Forming a Physical Hydrogel 189
Drug delivery and mathematical modeling: an historical perspective 189
High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1–Actin Complex as a New Potential Target for Therapy 189
Hydrogels mesh size evaluation 188
Cyclin E1, E2 and E2F1 targeted siRNAs down regulate the growth of coronary smooth muscle cell, thus showing their potential use in the prevention of in-stent restenosis 187
Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach 186
Improving siRNA Bio-Distribution and Minimizing Side Effects 182
SCHS SMART CREAM FOR A HEALTY SKIN 181
Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors 175
Xenograft zebrafish models for the development of novel anti-hepatocellular carcinoma molecules 175
Potential applications of small interferring RNA in the cardiovascular field 173
E2F1 as a molecular drug target in ovarian cancer 171
Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer 171
Proliferation of human primary vascular smooth muscle cells depends on serum response factor. 168
Nucleic Acids-based Aptamers and their applications 168
Uso di small interfering RNA (SIRNA) per il trattamento di patologie caratterizzate da iperproliferazione cellulare 166
In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer 166
Synthesis and characterization of polyaspartamide copolymers obtained by ATRP for nucleic acid delivery 164
Propaedeutic study for the delivery of nucleic acid-based molecules from PLGA microparticles and stearic acid nanoparticles 164
“Alpha-anomeric configuration of GT oligodeoxynucleotide leads to loss of specific aptameric and cytotoxic properties retained by the Beta-anomeric analog” 162
The targeting of the elongation factor 1A by a DNA aptamer impairs the viability of hepatocarcinoma cells 160
Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases 159
“The expression levels of the translational factors eEF1A1/2 correlate with the cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade” 159
A pivotal study in human prostate cancer tissues and cell lines to measure the expression levels of eukaryotic Elongation Factor 1A proteins and the effect of a nucleic acid-based GT75 aptamer 158
An Overview of siRNA Delivery Strategies for Urological Cancers 158
The Role of the eEF1A Family in Human Cancers 157
“Can TIE-2 expressing monocytes represent a novel marker for Hepatocellular Carcinoma? 156
USO SINERGICO DELLA REOLOGIA E DELLA RISONANZA MAGNETICA NUCLEARE A BASSO CAMPO PER CARATTERIZZARE L’ESPETTORATO DI PAZIENTI CON FIBROSI CISTICA 155
Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system 154
In Vitro and In Vivo Evaluation of the Effects of Drug 2c and Derivatives on Ovarian Cancer Cells 153
“Increase in therapeutic index of doxorubicin and vinblastine by aptameric oligonucleotide in human T-lymphoblastic drug sensitive and multidrug-resistance cells” 151
"Reduction of mdr1 gene amplification in human multidrug resistant LoVo dX cellline is promoted by triple-helix forming oligonucleotides" 151
null 150
SiRNAs targeted against cyclin E1, cyclin E2 and E2F1 down regulate the growth of Hepatocellular Carcinoma showing their potential use in the prevention of this type of tumor 149
Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches 148
SIMPLE, BIOCOMPATIBLE AND COST-EFFECTIVE INULIN BASED siRNA DELIVERY SYSTEMS 148
null 148
Role of E2F1-cycline1-cycline2 circuit in hepatocellular carcinoma cell proliferation and therapeutic potential of its down-regulation by siRNAs 146
Drug delivery and in vivo absorption 145
Role of E2F1–Cyclin E1-Cyclin E2 Circuit in Human Coronary Smooth Muscle Cell Proliferation and Therapeutic Potential of Its Downregulation by siRNAs 144
Hydrogel mesh size evaluation 142
“ Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell lines specifically binding to aptameric cytotoxic GT oligonucleotides” 138
null 136
Effects of various promoter derived sequences on the cleavage kinetic of an hammerhead ribozyme directed against cyclin E1 mRNA. 136
null 136
Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. 136
Totale 21.657
Categoria #
all - tutte 69.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.409


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021167 0 0 0 0 0 0 0 0 0 0 0 167
2021/20221.568 58 96 59 203 39 125 77 76 140 151 190 354
2022/20232.434 228 334 234 338 218 365 38 214 263 45 107 50
2023/20241.455 79 85 86 86 162 158 192 279 21 103 102 102
2024/20253.017 27 93 214 251 308 314 180 151 418 407 303 351
2025/20267.221 823 376 530 654 561 660 986 182 844 942 356 307
Totale 25.059